Natco Pharma Secures USFDA Tentative Approval for Generic Olaparib Tablets, Partnering with Alembic for U.S. Distribution
核心洞察
Natco Pharma received tentative USFDA approval for generic Olaparib tablets (100 mg and 150 mg), deemed bioequivalent to AstraZeneca's Lynparza®.
Alembic Pharmaceuticals will distribute the product in the U.S. market while Natco handles manufacturing, with ongoing Para IV litigation.
Olaparib tablets generated estimated U.S. sales of approximately USD 1.4 billion over the 12 months ending March 2026, per IQVIA data.
Natco Pharma Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for its Olaparib tablets in 100 mg and 150 mg strengths, marking a significant regulatory milestone for the Hyderabad-based pharmaceutical company. The approved Abbreviated New Drug Application (ANDA) establishes the product as bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lynparza® tablets, manufactured by AstraZeneca Pharmaceuticals (搜索) LP.
The announcement was confirmed through regulatory filings submitted to the National Stock Exchange of India (NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Under the partnership structure, Natco will be responsible for manufacturing the Olaparib tablets, while Alembic Pharmaceuticals Limited will manage distribution within the United States market.
Market Opportunity and Litigation Status
The commercial potential for generic Olaparib is substantial. According to IQVIA data, Olaparib tablets in 100 mg and 150 mg strengths achieved estimated sales of approximately USD 1.4 billion in the U.S. over the 12 months ending March 2026. This represents a significant market opportunity for the Natco-Alembic partnership, though the companies noted that the Para IV litigation concerning the product remains ongoing.
Regulatory Portfolio Expansion
For Alembic Pharmaceuticals, this tentative approval brings the company's cumulative total to 244 ANDA approvals from the USFDA. This portfolio consists of 224 final approvals and 20 tentative approvals, underscoring the company's continued expansion in the complex generic pharmaceutical market.
Natco Pharma's Capabilities
Natco Pharma describes itself as an R&D-centric and science-driven organization with a focus on oncology and targeted therapies. The company pursues molecules with limited competition in the U.S. market. Natco operates nine manufacturing sites and two R&D facilities in India, all approved by leading regulatory bodies including the U.S. FDA, Brazil ANVISA, Health Canada, and the World Health Organization (WHO), enabling the company to serve over 50 global markets.
Separate USFDA Communication Regarding Alembic
In a separate disclosure, Alembic Pharmaceuticals reported that the USFDA issued a Warning Letter dated July 10, 2026, to a Clinical Investigator associated with a bioequivalence study conducted at its Vadodara facility. The letter pertains to observations regarding the Informed Consent Form (ICF) used during the study. Alembic clarified that these observations do not relate to data integrity issues, and no restrictions have been imposed on the operations of its Bioequivalence Facility. The USFDA inspection that led to this correspondence was conducted between March 3, 2025, and March 7, 2025. Alembic stated that, based on a preliminary assessment, the regulatory action does not impose any material financial impact or operational restrictions on its Bioequivalence Facility. The company is coordinating with the Clinical Investigator to submit an appropriate response to the USFDA within the stipulated timeline.